Procept, which has developed a medical device that uses a waterjet for tissue removal, has closed a funding round led by pharmaceutical firm Novo.
US-based medical device maker Procept BioRobotics closed a $42m round on Tuesday led by pharmaceutical company Novo that also featured investment firm CPMG and undisclosed existing investors.
Procept has developed a medical device dubbed AquaBeam that enables minimally invasive removal of tissue using a waterjet.
The treatment, named aquablation by the company, is targeted and heat-free, and can be used to combat benign prostatic hyperplasia (BPH), a non-cancerous growth of the prostate.
The capital injection will fund a limited commercial…
